Implantation of a trabecular micro-bypass (iStent, Glaukos Corp.) in patients with open-angle glaucoma who are undergoing cataract surgery represents an alternative surgical approach that can provide clinically significant reductions in IOP and use of ocular hypotensive medications.
Non-penetrating Schlemm's canaloplasty may be a safe and effective alternative to standard trabeculectomy. A retrospective comparison study found no statistically significant differences in IOP reduction or medication usage at up to 1 year of follow-up. Adjunctive procedures and complications were similar in the two groups of patients, although no long-term hypotony was seen in the canaloplasty group.
Anti-vascular endothelial growth factor monotherapy useful option in patients with retinal angiomatous proliferation, study finds
Anti-vascular endothelial growth factor monotherapy appears to be an effective treatment for retinal angiomatous proliferation, according to results of a small, retrospective chart review. Although the results indicate that in most cases repeated injections would be needed to achieve improvement or stable vision, treatment based on ocular coherence tomography-confirmed presence of fluid could achieve outcomes similar to monthly injections.
An investigational compound for the treatment of dry eye disease consisting of a proprietary formulation of sodium hyaluronate ophthalmic solution 0.18% (Vismed, Lantibio Inc.) was shown to be safe and effective in a multicenter phase III trial conducted in the United States. A new drug application has been filed for the solution, which is already marketed in parts of Europe and Asia as a viscoelastic lubricant eye drop.
New software (MatchedFlicker, EyeIC) uses time series retinal photographs to convert change into motion and could improve the accuracy and speed of detecting glaucomatous progression.
Longer duration of use of monotherapy with prostaglandin analogues may be associated with lower annual costs of glaucoma treatment because adjunctive therapy is one of the primary factors affecting the cost of care, suggest findings of a retrospective analysis of a pharmacy claims database.
Bepotastine besilate 1.0% (Bepreve, ISTA Pharmaceuticals), an ocular allergy compound under new drug application review by the FDA, is effective in reducing ocular itching associated with allergic conjunctivitis and also seems to improve other allergy symptoms.
Complex visual hallucinations experienced by visually impaired patients are often indicative of Charles Bonnet syndrome. Individuals who experience these hallucinations usually understand that they are not real but will benefit from a doctor's explanation that they are associated with their vision loss and are unlikely to be a sign of mental illness.
Vascular endothelial growth factor antagonists will have greater potency, less specificity, ophthalmologist predicts
Antagonists of vascular endothelial growth factor provide a benefit for choroidal neovascularization and are promising for other retinal diseases, but they represent only the beginning of a transformation in the treatment of certain eye diseases, according to one ophthalmologist.
One year follow-up results of a small study of ranibizumab (Lucentis, Genentech) in patients with nonischemic retinal vein occlusion show that all treated patients gained VA or that VA remained stable, although this improvement was accompanied by decreases in contrast sensitivity and reading ability.